Abstract:CAR‐T‐cell therapy has shown remarkable promise in cancer treatment but faces significant resistance challenges. This review examines strategies to overcome resistance by targeting apoptotic pathways, including novel combination therapies and CAR constructs. Additionally, it highlights the impact of the tumor microenvironment and the potential of combining strategies to improve CAR‐T cell function and infiltration into tumors. Background Chimeric antigen receptor (CAR)‐T‐cell therapy has transformed cancer treatment, leading to remarkable clinical outcomes. However, resistance continues to be a major obstacle, significantly limiting its efficacy in numerous patients. Objectives This review critically examines the challenges associated with CAR‐T‐cell therapy, with a particular focus on the role of apoptotic pathways in overcoming resistance. Methods We explore various strategies to sensitize tumor cells to CAR‐T‐cell‐mediated apoptosis, including the use of combination therapies with BH3 mimetics, Mcl‐1 inhibitors, IAP inhibitors, and HDAC inhibitors. These agents inhibit anti‐apoptotic proteins and activate intrinsic mitochondrial pathways, enhancing the susceptibility of tumor cells to apoptosis. Moreover, targeting the extrinsic pathway can increase the expression of death receptors on tumor cells, further promoting their apoptosis. The review also discusses the development of novel CAR constructs that enhance anti‐apoptotic protein expression, such as Bcl‐2, which may counteract CAR‐T cell exhaustion and improve antitumor efficacy. We assess the impact of the tumor microenvironment (TME) on CAR‐T cell function and propose dual‐targeting CAR‐T cells to simultaneously address both myeloid‐derived suppressor cells (MDSCs) and tumor cells. Furthermore, we explore the potential of combining agents like PPAR inhibitors to activate the cGAS‐STING pathway, thereby improving CAR‐T cell infiltration into the tumor. Conclusions This review highlights that enhancing tumor cell sensitivity to apoptosis and increasing CAR‐T cell cytotoxicity through apoptotic pathways could significantly improve therapeutic outcomes. Targeting apoptotic proteins, particularly those involved in the intrinsic mitochondrial pathway, constitutes a novel approach to overcoming resistance. The insights presented herein lay a robust foundation for future research and clinical applications aimed at optimizing CAR‐T cell therapies.

Activation-induced cell death in CAR-T cell therapy

A Chimera Antigen Receptor Containing TLR4 Signaling Domain Enhances CAR-iMACs Polarization and Potency against Solid Tumors

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Enhanced radiation-induced immunogenic cell death activates chimeric antigen receptor T cells by targeting CD39 against glioblastoma

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR‐T‐Cell Therapy

Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Engineering T Cells with Hypoxia-Inducible Chimeric Antigen Receptor (hicar) for Selective Tumor Killing

Inactivation of TGF-β signaling in CAR-T cells

[Cell therapy's poster child: Chimeric antigen receptor T cell therapy]

The role of CD95 in modulating CAR T-cell therapy: Challenges and therapeutic opportunities in oncology

Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

4-1BB-encoding CAR causes cell death via sequestration of the ubiquitin-modifying enzyme A20

Activated aggregation‐induced emission therapeutics agents for triggering regulated cell death

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

New development in CAR-T cell therapy